Google links Axios npm supply chain attack to UNC1069 after trojanized versions 1.14.1 and 0.30.4 spread WAVESHAPER.V2, ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...

Caring for someone with ATTR amyloidosis can be physically and emotionally demanding. To reduce the chances of burnout, caregivers should also prioritize their own well-being. Factors such as ...

A PubMed search through June 30, 2025 identified 10 eligible comparative studies, pooling 5203 patients and using random-effects modeling to estimate mortality and cardiovascular hospitalization risk ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...

If you’ve been diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), you may be debating between two treatments: transthyretin (TTR) stabilizers and gene silencers. Both drug families are ...

Chicago, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The global amyloidosis therapeutics market was valued at 2.95 billion in 2024 and is expected to reach US$ 6.37 billion by 2033, growing at a CAGR of 9.20% ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...